References
- 1. Becerra-Bolaños Á., Armas-Domínguez A., Valencia L. et al. (2023) Pain Prevalence and Satisfaction with Pain Management in Inpatients: A Cross-Sectional Study. Healthcare (Basel), 11(24): 3191. doi: 10.3390/healthcare11243191.
- 2. www.iasp-pain.org/terminology?navItemNumber=576.
- 3. Rugnath R., Orzechowicz C., Newell C. et al. (2024) A Literature Review: The Mechanisms and Treatment of Neuropathic Pain-A Brief Discussion. Biomedicines, 12(1): 204.
- 4. Vieira W.F., Coelho D., Litwiler S. et al. (2024) Neuropathic Pain, Mood, and Stress-Related Disorders: A Literature Review of Comorbidity and Co-Pathogenesis. Neurosci. Biobehav. Rev., 105673. doi: 10.1016/j.neubiorev.2024.105673.
- 5. Baskozos G., Hébert H.L., Pascal M. et al. (2023) Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. Pain Rep., 8(2): e1066.
- 6. Doneddu P.E., Pensato U., Iorfida A. et al. (2023) Neuropathic Pain in the Emergency Setting: Diagnosis and Management. J. Clin. Med., 12(18): 6028.
- 7. Price R., Smith D., Franklin G. et al. (2022) Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology, 98(1): 31–43.
- 8. Pop-Busui R., Ang L., Boulton A. et al. (2022) Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy. Arlington (VA): American Diabetes Association.
- 9. Blonde L., Umpierrez G.E., Reddy S.S. et al. (2022) American Association of Clinical Endocrinology Clinical Practice Guideline: developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr. Pract., 28(10): 923–1049.
- 10. www.ncbi.nlm.nih.gov/books/NBK552848/.
- 11. Mu A., Weinberg E., Moulin D. et al. (2017) Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Can. Fam. Physician, 63(11): 844–852.
- 12. Finnerup N.B., Attal N., Haroutounian S. et al. (2015) Pharmacotherapy for neuropathic pain in adults: Systematic review, meta-analysis and updated NeuPSig recommendations. Lancet Neurol., 14: 162–173. doi: 10.1016/S1474-4422(14)70251-0.
- 13. Derry S., Bell R.F., Straube S. et al. (2019) Cochrane Database Syst. Rev., 1(1): CD007076.
- 14. Національні настанови з керування хронічного болю (2023) http://www.dec.gov.ua/wp-content/uploads/2023/04/kn-2023-hb-u-doroslyh.pdf.
- 15. Yeh Y.C., Cappelleri J.C., Marston X. et al. (2021) Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database study. PLoS One, 16(1): e0242467.
- 16. Alexander J.Jr., Edwards R.A., Manca L. et al. (2018) Dose Titration of Pregabalin in Patients with Painful Diabetic Peripheral Neuropathy: Simulation Based on Observational Study Patients Enriched with Data from Randomized Studies. Adv. Ther., 35(3): 382–394.
- 17. Mallick-Searle T., Adler J.A. (2024) Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options. J. Pain Res., 17: 1005–1028.
- 18. Evoy K.E., Covvey J.R., Peckham A. et al. (2019) Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res. Social Adm. Pharm., 15(8): 953–958.
- 19. Evoy K.E., Sadrameli S., Contreras J. et al. (2021) Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs, 81(1): 125–156.
- 20. Kiliç Z., Aydin Özaslan E. (2023) Abuse and addiction in gabapentinoid drug users for neuropathic pain. Eur. Rev. Med. Pharmacol. Sci., 27(12): 5378–5389.
- 21. Pickering G., Marcoux M., Chapiro S. et al. (2016) An Algorithm for Neuropathic Pain Management in Older People. Drugs Aging., 33(8): 575–583.
- 22. Semel D., Murphy T., Zlateva G. et al. (2010) Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam. Pract., 11: 85.
- 23. Akazawa M., Igarashi A., Ebata N. et al. (2019) A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan. J. Pain Res., 12: 2785–2797. doi: 10.2147/JPR.S203712.
- 24. Zeng F., Wang M., Zhang D. (2021) Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China. Ann. Palliat. Med., 10(4): 4493–4501.